Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Neither the Summary of Product Characteristics (SmPC) for Wegovy nor that for lisdexamfetamine lists the other as a formal contraindication, and there is no official guidance from NICE, MHRA, or the British National Formulary (BNF) prohibiting their co-administration
10.1038/mp.2012.141 23 HarastaA
Second, you must be seeing therapeutic effects like appetite suppression and weight changes
Injection site redness can happen to anyone receiving an injectable medication but is most common when a medication is given subcutaneously
Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
US$ 25.35
US$ 20.65
US$ 24.84
